Plain-English translation of NCT06440629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a personalized approach to dosing adalimumab — a medication that reduces inflammation in rheumatoid arthritis — can keep your disease more stable than the standard fixed-dose approach. The personalized approach uses regular blood tests to measure how much medication is in your system and whether your body has developed antibodies against it, then adjusts your dose accordingly. The goal is to help more people maintain disease control without experiencing flares.
Many people taking this medication have different drug levels in their blood, and some develop antibodies that make the treatment less effective, leading to disease flares. This trial aims to see if monitoring these levels and adjusting doses proactively can prevent flares and keep your disease stable better than the standard approach.
You will be randomly assigned to either the personalized dosing group or the standard dosing group for 18 months. You will visit the clinic at baseline and at 4, 8, 12, and 18 months, with shorter digital check-ins at other timepoints. At each visit, blood will be drawn to measure your medication level and antibodies, and your arthritis will be assessed. Depending on which group you're in, your medication dose may be adjusted based on these results, or you'll continue on your standard dose without knowing these test results.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Austria
Italy
Norway